Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth
09 Mayo 2024 - 6:30AM
Business Wire
Scipher Medicine, an AI-enabled precision immunology company,
today announced the appointment of Reginald Seeto, MBBS*, as Chief
Executive Officer and President. Scipher developed SpectraTM, a
proprietary AI platform that has been used to build both an
autoimmune diagnostic and an emerging biopharmaceutical business.
In the diagnostics business, PrismRA® was recently approved by
MolDx for therapy selection in rheumatoid arthritis patients, and
in the biopharmaceutical business, recent deals have focused on
generating novel target discovery and data insights for
partners.
Dr. Seeto is a seasoned CEO and Board Member who brings more
than two decades of leadership experience across both diagnostic
and therapeutic companies.
"Reg has an established leadership track record in building both
products and companies by setting bold strategies that can be
delivered through high performing teams. His deep understanding of
the diagnostic and therapeutic industry makes him the right person
to lead Scipher going forward," said Samir Kaul, Managing Director
at Khosla Ventures and a member of the Scipher Board of
Directors.
Dr. Seeto was most recently the CEO and President of CareDx
("CDNA"), a company focused on the transplant patient. Under Dr.
Seeto's leadership, CareDx was recognized as one of the
fastest-growing companies in North America by Deloitte's Technology
Fast 500 driven by its innovative transplant diagnostic business.
During his tenure, he grew business lines across this patient
journey, including building a denovo patient and digital solution
business through acquisitions and partnerships. Prior to this, he
was the Chief Operating Officer at Ardelyx ("ARDX"), and EVP of
Corporate Development and Strategy at Medimmune, the biologics
division of AstraZeneca (“AZN”). Earlier in his career, he held
both US and global leadership positions at Boehringer Ingelheim and
Organon, respectively. He launched his career as a
physician-scientist with both clinical and research roles and
worked as a strategy consultant at McKinsey & Company.
"I am thrilled to be joining Scipher, where we can grow the
business because of the ongoing unmet need in treating patients
with autoimmune disease and with the significant opportunity to
partner with biopharmaceutical companies." said Dr Seeto,
“Importantly, one of the key attractions in joining was the ability
to work with the world-class caliber board at Scipher."
Recently, Scipher has also appointed Glenn Muir as Independent
Director to its Board and as Chair of the Audit Committee. Muir
brings over 30 years of experience to the role, with a
distinguished career in the life sciences industry. Most notably,
he spent 26 years at Hologic, Inc., a leading multinational medical
device and diagnostics company. At Hologic, Muir served as Chief
Financial Officer (CFO) and Executive Vice President, playing a key
role in the company's remarkable growth. He helped steer Hologic's
evolution from a venture-backed startup to a publicly traded,
diversified organization with over 5,000 employees and $2.5 billion
in revenue. Muir's impressive track record extends beyond Hologic.
He currently serves on the boards of directors for several publicly
traded companies in the life sciences sector, including Repligen
Corporation, G1 Therapeutics, Inc., and Neuronetics, Inc. He has
also held board positions at ReWalk Robotics Ltd. and RainDance
Technologies, Inc.
"I am honored to be appointed Chair of the Audit Committee at
Scipher," said Mr. Muir. "Scipher's mission to revolutionize
precision immunology through its innovative data platform is truly
groundbreaking. I look forward to leveraging my experience to
contribute to the company's continued success."
"We are thrilled to welcome Glenn to the Audit Committee Chair
role," said Tim Anderson, Managing Director at Blue Own Capital and
a member of the Scipher Board of Directors "his extensive financial
expertise and proven leadership in the life sciences industry will
be invaluable to Scipher as we pursue our ambitious growth plans.
His addition to Scipher underscores the company’s commitment to
strong corporate governance and financial oversight."
Seeto and Muir’s appointment mark a significant step forward for
Scipher as the company positions itself for continued growth within
the field of precision immunology.
*MBBS is equivalent to a MD in the United States
About Scipher Medicine
Scipher Medicine, a precision immunology company matching each
patient with their most effective therapy, believes that patients
deserve simple answers to treatment options based on scientific
data. Using Spectra™, a proprietary network medicine platform,
Scipher commercializes tests revealing a person’s unique molecular
disease signature and match it to the most effective therapy,
ensuring optimal treatment from day one. The patient molecular data
generated from our tests further supports the discovery and
development of novel and more effective therapeutics. Scipher
partners with leading payers, healthcare providers, and
pharmaceutical companies to bring solutions to patients across
diseases. To learn more about Scipher visit sciphermedicine.com and
follow Scipher Medicine on Facebook, X, and LinkedIn.
About PrismRA®
PrismRA is a revolutionary blood test bringing precision
medicine to the treatment of rheumatoid arthritis, which affects 20
million patients globally. From a routine blood draw, the PrismRA
test analyzes an individual’s molecular signature, helping identify
who is unlikely to adequately respond to TNFi therapy, the world’s
largest selling drug class, so non-responders can be prescribed
alternative effective therapy and avoid unnecessary dose
escalations or drug cycles. Providers now have objective data to
inform therapeutic decision-making and give patients the best
chance of achieving treatment targets and improving clinical
outcomes. For more information, please visit PrismRA.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509660679/en/
Scipher: Corporate Communications: Jaclyn Vincent
PR@scipher.com 801-910-5552